Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data

CHICAGO – Merck showed dramatic HDL and LDL cholesterol effects and no safety concerns in the Phase III DEFINE study of anacetrapib, but it is still planning to wait to submit the cholesteryl ester transfer protein (CETP) inhibitor until the conclusion of a major outcomes trial.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet